Angiotensin converting enzyme inhibitors and incidence of lung cancer in a population based cohort of common data model in Korea

• Published in: Scientific reports 2021-09, Vol.11 (1), p.18576-18576, Article 18576
• Main Authors: Lee, Seung-Hwa, Chun, Kwang Jin, Park, Jungchan, Kim, Jinseob, Sung, Ji Dong, Park, Rae Woong, Choi, Jinwook, Yang, Kwangmo
• Format: Article
• Language: English
• Subjects: 692/308/409; 692/4019; Angiotensin; Angiotensin-converting enzyme inhibitors; Data models; Diuretics; Enzyme inhibitors; Enzymes; Humanities and Social Sciences; Lung cancer; multidisciplinary; Observational studies; Patients; Peptidyl-dipeptidase A; Science; Science (multidisciplinary)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-97989-8

Contradictory findings exist about association of angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) with lung cancer development. This was a retrospective observational cohort study that used data from 7 hospitals in Korea, converted to the Observational Medical Outcomes Partnership Common Data Model. The primary outcome was occurrence of lung cancer. A total of 207,794 patients across the 7 databases was included in the final analysis; 33,230 (16%) were prescribed ACEi and 174,564 (84%) were prescribed ARB. Crude analysis adjusted for sex and age showed higher incidence of lung cancer in the ACEi group compared to the ARB group (hazard ratio [HR], 1.46; 95% confidence rate [CI], 1.08–1.97). After propensity-score matching, 30,445 pairs were generated, and there was no difference in incidence of lung cancer between the two groups (HR, 0.93; 95% CI, 0.64–1.35). Patients prescribed ACEi showed no difference in incidence of lung cancer development compared to those using ARB. This finding provides evidence on the association between ACEi and occurrence of lung cancer.